{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:15:57Z","timestamp":1759990557208,"version":"3.41.0"},"reference-count":13,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[1993,7,1]],"date-time":"1993-07-01T00:00:00Z","timestamp":741484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[1993,7]]},"abstract":"<jats:p>The effects of 20 mg Zolpidem were studied in an open, polysomnographically-monitored 179 day trial in 14 elderly psychiatric patients suffering from severe insomnia. After a placebo run-in of 7 days, Zolpidem was given for 179 days followed by a 30-day wash-out period. Polysomnographic recordings (PSG) were performed just before active treatment; 30, 90 and 179 days into the treatment period; and at the end of the wash-out period. Statistically significant improvements in total sleep time, sleep efficiency and percentage of rapid eye movement sleep were observed after 30 days, all of which were maintained at 179 days. Sleep stages 1 \u2212 4 all changed, with a significant decrease in percentage of stage 1, and a significant increase in both percentages of stage 2 and 3, and duration of stages 3 and 4 at the end of active treatment. After a 90-day follow-up period, only stage 3 sleep and sleep efficiency were no longer significantly changed compared to baseline, all other criteria showing maintenance of efficacy. Slow-wave sleep, which was increased during active treatment, decreased in the follow-up period. No serious adverse events were observed. These results suggest that, contrary to other hypnotics, Zolpidem, after long-term administration, improves objective sleep parameters and may normalize a disturbed sleep architecture.<\/jats:p><jats:p>Les effets du Zolpidem (20 mg) ont \u00e9t\u00e9 \u00e9tudi\u00e9s chez 14 patients \u00e2g\u00e9s, psychiatriques, pr\u00e9sentant une insomnie s\u00e9v\u00e8re, dans un essai ouvert de 179 jours, avec enregistrement polysomnographique (PSG). Apr\u00e8s 7 jours sous placebo, les patients recevaient le Zolpidem pendant une p\u00e9riode de 179 jours, suivie de 90 jours de sevrage sans traitement. Les enregistrements PSG du sommeil \u00e9taient effectu\u00e9s juste avant la p\u00e9riode de traitement actif, puis, sous traitement, aux jours 30, 90 et 179, et \u00e0 la fin de la p\u00e9riode de sevrage. Au contr\u00f4le du 1er mois, la dur\u00e9e totale de sommeil, son efficacit\u00e9, et le pourcentage de sommeil paradoxal (REM) \u00e9taient significativement augment\u00e9s, cette augmentation se maintenant pendant les 179 jours de traitement. Les stades 1 \u00e0 4 du sommeil \u00e9taient tous modifi\u00e9s, avec, \u00e0 la fin du traitement, une diminution significative du pourcentage de stade 1 et une augmentation significative du pourcentage des stades 2 et 3, ainsi que de la dur\u00e9e des stades 3 et 4. A I'issue des 90 jours de sevrage, seuls l'efficacit\u00e9 du sommeil et le pourcentage de stade 3 n'\u00e9taient plus significativement modifi\u00e9s par rapport aux valeurs initiales, l'efficacit\u00e9 se maintenant pour tous les autres crit\u00e8res. Le sommeil lent profond, augment\u00e9 sous traitement, diminuait pendant la p\u00e9riode de sevrage. II n'a pas \u00e9t\u00e9 observ\u00e9 d'effets ind\u00e9sirables graves. Ces r\u00e9sultats sugg\u00e9rent que, contrairement aux autres hypnotiques, le Zolpidem, administr\u00e9 \u00e0 long terme, am\u00e9liore les param\u00e8tres objectifs du sommeil et peut restorer une architecture du sommeil alt\u00e9r\u00e9e.<\/jats:p><jats:p>Die Wirkung von 20 mg Zolpidem wurde w\u00e4hrend einer offenen 179 t\u00e4gigen kontrollierten polysomnographischen Studie bei 14 \u00e4lteren psychiatrischen Patienten mit schweren Schlafst\u00f6rungen untersucht. Nach einer 7 t\u00e4gigen Placebo Run-in-Phase, wurde Zolpidem f\u00fcr 179 Tage verabreicht, anschlie\u00dfend wurde eine 90 t\u00e4gigen<\/jats:p><jats:p>Auswasch-Periode durchgef\u00fchrt. Polysomnographische Aufzeichnungen wurden unmittelbar vor Beginn der aktiven Behandlungsphase, am 30., 90. und 179. Tag der aktiven Behandlungsphase und am Ende der Auswasch-Periode durchgef\u00fchrt. Die Gesamtschlafzeit, die Schlafeffizienz und der Prozentsatz an REM-Schlaf waren bei der Kontrolle am Ende des ersten Monates statistisch signifikant vermehrt. Diese Besserungen blieben bis zum Ende der Behandlung (179 Tage) erhalten. Die Schlafstadien 1 bis 4 waren insgesamt ge\u00e4ndert mit einer signifikanten Reduktion des Schlafstadiums 1 und einer signifikanten Erh\u00f6hung sowohl des Prozentsatzes f\u00fcr die Schlafstadien 2 und 3 als auch der Dauer der Schlafstadien 3 und 4 am Ende der aktiven Behandlungsphase. Am Ende der nachfolgenden 90 t\u00e4gigen Auswasch-Periode ergab sich nur f\u00fcr den Anteil des Schlafstadiums 3 und die Schlafeffizienz keine signifikante \u00c4nderung in Bezug auf die Ausgangswerte, alle anderen Parameter belegten eine fortdauernde Wirksamkeit. Der \u2018Slow Wave Sleep', der w\u00e4hrend der aktiven Behandlung zunahm, verringerte sich w\u00e4hrend der nachfolgenden Auswasch-Periode. Es wurden keine schwerwiegenden unerw\u00fcnschten Ereignisse beobachtet. Diese Ergebnisse deuten darauf hin, da\u00df im Gegensatz zu anderen Hypnotika Zolpidem nach einer Langzeitverabreichung die objektiven Schlafparameter verbessert und eine gest\u00f6rte Schlafarchitektur wieder normalisieren kann.<\/jats:p>","DOI":"10.1177\/030006059302100402","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T05:07:20Z","timestamp":1484629640000},"page":"171-184","source":"Crossref","is-referenced-by-count":36,"title":["Long-Term Polysomnographic Study of the Efficacy and Safety of Zolpidem in Elderly Psychiatric In-Patients with Insomnia"],"prefix":"10.1177","volume":"21","author":[{"given":"J","family":"Rummer","sequence":"first","affiliation":[{"name":"Landeskrankenhaus Nordschwarzwald, Fachklinik Psychiatrie und Neurologie, Calw-Hirsau, Germany"}]},{"given":"L","family":"Guendel","sequence":"additional","affiliation":[{"name":"Landeskrankenhaus Nordschwarzwald, Fachklinik Psychiatrie und Neurologie, Calw-Hirsau, Germany"}]},{"given":"J","family":"Linden","sequence":"additional","affiliation":[{"name":"Landeskrankenhaus Nordschwarzwald, Fachklinik Psychiatrie und Neurologie, Calw-Hirsau, Germany"}]},{"given":"FX","family":"Eich","sequence":"additional","affiliation":[{"name":"Synth\u00e9labo Recherche, M\u00fcnchen, Germany"}]},{"given":"P","family":"Attal","sequence":"additional","affiliation":[{"name":"Synth\u00e9labo Recherche (LERS), Bagneux, France"}]},{"given":"JP","family":"Coquelin","sequence":"additional","affiliation":[{"name":"Synth\u00e9labo Recherche (LERS), Bagneux, France"}]},{"given":"HJ","family":"Kyrein","sequence":"additional","affiliation":[{"name":"Synth\u00e9labo Recherche, M\u00fcnchen, Germany"}]}],"member":"179","published-online":{"date-parts":[[1993,7,1]]},"reference":[{"key":"bibr1-030006059302100402","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1982.tb03700.x"},{"key":"bibr2-030006059302100402","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197601040-00003"},{"key":"bibr3-030006059302100402","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198908033210507"},{"key":"bibr4-030006059302100402","doi-asserted-by":"publisher","DOI":"10.1007\/BF00572441"},{"key":"bibr5-030006059302100402","first-page":"13","volume":"16","author":"Benavides J","year":"1990","journal-title":"Encephale"},{"key":"bibr6-030006059302100402","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0022-3565(25)24899-6","volume":"237","author":"Depoortere H","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr7-030006059302100402","unstructured":"Bianchetti G, Dubruc C, Thiercelin JF, Clinical pharmacokinetics of Zolpidem in various physiological and pathological conditions. In: Imidazopyridines in Sleep Disorders (Sauvanet JP, Langer SZ, Morselli PL, eds.). New York; Raven Press, 1988; pp155\u2013163."},{"key":"bibr8-030006059302100402","unstructured":"Zander KJ, Dietrich B, Kubicki S. Placebo controlled polysomnographic efficacy of a 2-week treatment with 10mg Zolpidem in chronic insomniacs [Abstract] 9th European Congress of Sleep Research, Jerusalem, Israel 4\u20139 September 1988; p231."},{"key":"bibr9-030006059302100402","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558070"},{"volume-title":"A Manual of Standardized Terminology, Techniques and Scoring Values for Sleep Stages of Human Subjects.","author":"Rechtschaffen A","key":"bibr10-030006059302100402"},{"volume-title":"Clinical Neurology of Aging","year":"1984","author":"Katz RI","key":"bibr11-030006059302100402"},{"key":"bibr12-030006059302100402","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198122020-00001"},{"key":"bibr13-030006059302100402","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199040020-00008"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030006059302100402","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030006059302100402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T14:50:01Z","timestamp":1749912601000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/030006059302100402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,7]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1993,7]]}},"alternative-id":["10.1177\/030006059302100402"],"URL":"https:\/\/doi.org\/10.1177\/030006059302100402","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"type":"print","value":"0300-0605"},{"type":"electronic","value":"1473-2300"}],"subject":[],"published":{"date-parts":[[1993,7]]}}}